Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders

References

• Kessler RC, Berglund P, Demler O et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA289(23), 3095–3105 (2003).
   PubMed Web of Science ®Google Scholar
• Kessler RC, McGonagle KA, Zhao S et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry51(1), 8–19 (1994).
   PubMed Web of Science ®Google Scholar
• Nutt DJ. Care of depressed patients with anxiety symptoms. J. Clin. Psychiatry60(Suppl. 17), 23–27; discussion 46–48 (1999).
   PubMedGoogle Scholar
• Lenze EJ, Mulsant BH, Shear MK et al. Comorbid anxiety disorders in depressed elderly patients. Am. J. Psychiatry157(5), 722–728 (2000).
   PubMed Web of Science ®Google Scholar
• Rouillon F. Anxiety with depression: a treatment need. Eur. Neuropsychopharmacol.9(Suppl. 3), S87–S92 (1999).
   Google Scholar
• Lydiard RB. Social anxiety disorder: comorbidity and its implications. J. Clin. Psychiatry62(Suppl. 1), 17–23; discussion 24 (2001).
   Google Scholar
• Ballenger JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J. Clin. Psychiatry60(Suppl. 22), 29–34 (1999).
   PubMed Web of Science ®Google Scholar
• Mittal D, Fortney JC, Pyne JM, Edlund MJ, Wetherell JL. Impact of comorbid anxiety disorders on health-related quality of life among patients with major depressive disorder. Psychiatr. Serv.57(12), 1731–1737 (2006).
   PubMed Web of Science ®Google Scholar
• Thase ME. Treatment of severe depression. J. Clin. Psychiatry61(Suppl. 1), 17–25 (2000).
   PubMed Web of Science ®Google Scholar
• Sonawalla SB, Fava M. Severe depression: is there a best approach? CNS Drugs15(10), 765–776 (2001).
   PubMed Web of Science ®Google Scholar
• Olesen J, Leonardi M. The burden of brain diseases in Europe. Eur. J. Neurol.10(5), 471–477 (2003).
   PubMed Web of Science ®Google Scholar
• Sobocki P, Jonsson B, Angst J, Rehnberg C. Cost of depression in Europe. J. Ment. Health Policy Econ.9(2), 87–98 (2006).
   PubMed Web of Science ®Google Scholar
• Greenberg PE, Kessler RC, Birnbaum HG et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J. Clin. Psychiatry64(12), 1465–1475 (2003).
   PubMed Web of Science ®Google Scholar
• Sobocki P, Ekman M, Agren H et al. Resource-use and cost of patients treated for depression in primary care. Presented at: The 11th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research. Philadelphia, PA, USA, 20–24 May 2006 (Abstract PMH17).
   Google Scholar
• Berto P, D’Ilario D, Ruffo P, Di Virgilio R, Rizzo F. Depression: cost-of-illness studies in the international literature, a review. J. Ment. Health Policy Econ.3(1), 3–10 (2000).
   PubMedGoogle Scholar
• Einarson TR. Evidence based review of escitalopram in treating major depressive disorder in primary care. Int. Clin. Psychopharmacol.19(5), 305–310 (2004).
   PubMed Web of Science ®Google Scholar
• Rush AJ, Kraemer HC, Sackeim HA et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology31(9), 1841–1853 (2006).
   PubMed Web of Science ®Google Scholar
• Sobocki P, Ekman M, Agren H, Runeson B, Jonsson B. The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression. Int. J. Clin. Pract.60(7), 791–798 (2006).
   PubMed Web of Science ®Google Scholar
• Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol. Psychiatry50(5), 345–350 (2001).
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Reines EH, Guiton C, Weiller E. Escitalopram therapy for major depression and anxiety disorders. Ann. Pharmacother.41(10), 1583–1592 (2007).
   PubMed Web of Science ®Google Scholar
• Mork A, Kreilgaard M, Sanchez C. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology45(2), 167–173 (2003).
   PubMed Web of Science ®Google Scholar
• Sanchez C, Bogeso KP, Ebert B, Reines EH, Braestrup C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl)174(2), 163–176 (2004).
   PubMed Web of Science ®Google Scholar
• Cipralex® Product Monograph. H. Lundbeck A/S. Copenhagen, Denmark. (2007).
   Google Scholar
• Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J. Clin. Psychiatry63(4), 331–336 (2002).
   PubMed Web of Science ®Google Scholar
• Colonna L, Reines EH, Andersen HF. Escitalopram is well-tolerated and more efficacious than citalopram in long-term treatment of moderately depressed patients. Int. J. Psychiatry Clin. Pract.6, 243–244 (2002) (Abstract P205).
   Google Scholar
• Lepola UM, Loft H, Reines EH. Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int. Clin. Psychopharmacol.18(4), 211–217 (2003).
   PubMed Web of Science ®Google Scholar
• Wade A, Michael Lemming O, Bang Hedegaard K. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int. Clin. Psychopharmacol.17(3), 95–102 (2002).
   PubMed Web of Science ®Google Scholar
• Demyttenaere K, Hemels ME, Hudry J, Annemans L. A cost–effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin. Ther.27(1), 111–124 (2005).
   PubMed Web of Science ®Google Scholar
• François C, Sintonen H, Toumi M. Introduction of escitalopram, a new SSRI in Finland: comparison of cost–effectiveness between other SSRIs and SNRI for the treatment of depression and estimation of budgetary impact. J. Drug Assess.5, 221–237 (2002).
   Google Scholar
• François C, Toumi M, Aakhus AM, Hansen K. A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost–effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway. Eur. J. Health Econ.4(1), 12–19 (2003).
   PubMedGoogle Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry134, 382–389 (1979).
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry23, 56–62 (1960).
   PubMed Web of Science ®Google Scholar
• Lam RW, Michalak EE, Swinson RP. Assessment Scales in Depression, Mania and Anxiety. Taylor & Francis, London, UK 84–85 (2005)
   Google Scholar
• Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J. Clin. Psychiatry65(1), 44–49 (2004).
   PubMed Web of Science ®Google Scholar
• Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int. Clin. Psychopharmacol.20(3), 131–137 (2005).
   PubMed Web of Science ®Google Scholar
• Boulenger JP, Huusom AK, Florea I, Baekdal T, Sarchiapone M. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr. Med. Res. Opin.22(7), 1331–1341 (2006).
   PubMed Web of Science ®Google Scholar
• Auquier P, Robitail S, Llorca P-M, Rive B. Comparison of escitalopram and citalopram efficacy: a meta-analysis. Int. J. Psych. Clin. Pract.7(4), 259–268 (2003).
   PubMed Web of Science ®Google Scholar
• Lançon C, Verpillat P, Annemans L, Despiegel N, Francois C. Escitalopram in major depressive disorder: clinical benefits and cost effectiveness versus citalopram. Int. J. Psych. Clin. Pract.11(1), 44–52 (2007).
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J. Psychiatry Neurosci.31(2), 122–131 (2006).
   PubMed Web of Science ®Google Scholar
• Wade A, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr. Med. Res. Opin.23(7), 1605–1614 (2007).
   PubMed Web of Science ®Google Scholar
• Khan A, Bose A, Alexopoulos GS et al. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin. Drug Investig.27(7), 481–492 (2007).
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Greist JH, Mallinckrodt CH et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr. Med. Res. Opin.23(2), 401–416 (2007).
   PubMed Web of Science ®Google Scholar
• Azorin JM, Llorca PM, Despiegel N, Verpillat P. Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder. Encephale30(2), 158–166 (2004).
   PubMed Web of Science ®Google Scholar
• Llorca PM, Azorin JM, Despiegel N, Verpillat P. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int. J. Clin. Pract.59(3), 268–275 (2005).
   PubMed Web of Science ®Google Scholar
• Lam RW, Andersen HF. The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis. Pharmacopsychiatry39(5), 180–184 (2006).
   PubMed Web of Science ®Google Scholar
• Dhillon S, Scott LJ, Plosker GL. Escitalopram: a review of its use in the management of anxiety disorders. CNS Drugs20(9), 763–790 (2006).
   PubMed Web of Science ®Google Scholar
• Davidson JR, Bose A, Korotzer A, Zheng H. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress. Anxiety19(4), 234–240 (2004).
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Huusom AK, Maehlum E. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Br. J. Psychiatry189, 264–272 (2006).
   PubMed Web of Science ®Google Scholar
• Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J. Affect. Disord.87(2–3), 161–167 (2005).
   PubMed Web of Science ®Google Scholar
• Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann. Clin. Psychiatry17(2), 65–69 (2005).
   PubMedGoogle Scholar
• Allgulander C, Florea I, Huusom AK. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int. J. Neuropsychopharmacol.9(5), 495–505 (2006).
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Nil R, Durr-Pal N, Loft H, Boulenger JP. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J. Clin. Psychiatry66(10), 1270–1278 (2005).
   PubMed Web of Science ®Google Scholar
• Kasper S, Stein DJ, Loft H, Nil R. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br. J. Psychiatry186(3), 222–226 (2005).
   PubMed Web of Science ®Google Scholar
• Pallanti S, Quercioli L. Resistant social anxiety disorder response to escitalopram. Clin. Pract. Epidemol. Ment. Health2, 35 (2006).
   PubMedGoogle Scholar
• Lader M, Stender K, Burger V, Nil R. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress. Anxiety19(4), 241–248 (2004).
   PubMed Web of Science ®Google Scholar
• Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry64(11), 1322–1327 (2003).
   PubMed Web of Science ®Google Scholar
• Stein DJ, Andersen EW, Tonnoir B, Fineberg N. Escitalopram in obsessive–compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr. Med. Res. Opin.23(4), 701–711 (2007).
   PubMed Web of Science ®Google Scholar
• Fineberg NA, Tonnoir B, Lemming O, Stein DJ. Escitalopram prevents relapse of obsessive–compulsive disorder. Eur. Neuropsychopharmacol.17(6–7), 430–439 (2007).
   PubMed Web of Science ®Google Scholar
• Jorgensen TR, Stein DJ, Despiegel N et al. Cost–effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom. Ann. Pharmacother.40(10), 1752–1758 (2006).
   PubMed Web of Science ®Google Scholar
• Erder MH, Sharma D, Saikali K. A comparison of total direct costs of escitalopram vs. paroxetine in generalized anxiety disorder (GAD). Presented at: the 6th European Conference on Health Economics.Budapest, Hungary, 6–9 July 2006 (P62).
   Google Scholar
• Erder MH, Sharma D, Saikali K. A comparison of total direct costs of escitalopram vs. paroxetine in generalized anxiety disorder (GAD). Presented at: the 26th Annual Meeting of the Anxiety Disorders Association of America. Miami, FL, USA, 23–26 March (2006) (P379).
   Google Scholar
• Servant D, Montgomery SA, François C, Despiegel N. Cost–effectiveness of escitalopram versus placebo in relapse prevention in patients with social anxiety disorder. Presented at: The 8th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research. Arlington, VA, USA 18–21 May 2003 (Abstract PMH2).
   Google Scholar
• Colonna L, Andersen HF, Reines EH. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr. Med. Res. Opin.21(10), 1659–1668 (2005).
   PubMed Web of Science ®Google Scholar
• Ballenger JC, Davidson JR, Lecrubier Y et al. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J. Clin. Psychiatry59(Suppl. 8), 47–54 (1998).
   Google Scholar
• Rudolph RL. Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors. Acta Psychiatr. Scand.415(Suppl.), 24–30 (2002).
   Google Scholar
• Bren L. The importance of patient-reported outcomes. It’s all about the patients. FDA Consum.40(6), 26–32 (2006).
   Google Scholar
• Ringash J, O’Sullivan B, Bezjak A, Redelmeier DA. Interpreting clinically significant changes in patient-reported outcomes. Cancer110(1), 196–202 (2007).
   PubMed Web of Science ®Google Scholar
• Svanborg P, Asberg M. A new self-rating scale for depression and anxiety states based on the Comprehensive Psychopathological Rating Scale. Acta Psychiatr. Scand.89(1), 21–28 (1994).
   PubMed Web of Science ®Google Scholar
• Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol. Bull.29(2), 321–326 (1993).
   PubMed Web of Science ®Google Scholar
• Bech P, Tanghoj P, Cialdella P, Andersen HF, Pedersen AG. Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int. J. Neuropsychopharmacol.7(3), 283–290 (2004).
   PubMed Web of Science ®Google Scholar
• Allgulander C, Jorgensen T, Wade A et al. Health-related quality of life (HRQOL) among patients with generalised anxiety disorder: evaluation conducted alongside an escitalopram relapse prevention trial. Curr. Med. Res. Opin.23(10), 2543–2549(2007).
   PubMed Web of Science ®Google Scholar
• Bandelow B, Stein DJ, Dolberg OT, Andersen HF, Baldwin DS. Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Pharmacopsychiatry40(4), 152–156 (2007).
   PubMed Web of Science ®Google Scholar
• Lerner D, Adler DA, Chang H et al. Unemployment, job retention, and productivity loss among employees with depression. Psychiatr. Serv.55(12), 1371–1378 (2004).
   PubMed Web of Science ®Google Scholar
• Fantino B, Moore N, Verdoux H, Auray JP. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder. Int. Clin. Psychopharmacol.22(2), 107–115 (2007).
   PubMed Web of Science ®Google Scholar
• Wade AG, Fernandez JL, Francois C et al. A pharmacoeconomic comparison of escitalopram and duloxetine in treatment of major depressive disorder (MDD) in the United Kingdom. Presented at: The 10th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research. Dublin, Ireland, 20–23 October 2007 (Abstract PMH60).
   Google Scholar
• Lançon C, Sapin C, Note I, Farisse J. Comparison of escitalopram and citalopram in outpatients with severe major depressive disorder: a prospective, naturalistic, 8-week study. Int. J. Psych. Clin. Pract.10(2), 131–137 (2006).
   PubMed Web of Science ®Google Scholar
• Moller HJ, Langer S, Schmauss M. Escitalopram in clinical practice: results of an open-label trial in outpatients with depression in a naturalistic setting in Germany. Pharmacopsychiatry40(2), 53–57 (2007).
   PubMed Web of Science ®Google Scholar
• Winkler D, Pjrek E, Moser U, Kasper S. Escitalopram in a working population: results from an observational study of 2378 outpatients in Austria. Hum. Psychopharmacol.22(4), 245–251 (2007).
   PubMed Web of Science ®Google Scholar
• Wade A, Despiegel N, Heldbo Reines E. Escitalopram in the long-term treatment of major depressive disorder. Ann. Clin. Psychiatry18(2), 83–89 (2006).
   PubMedGoogle Scholar
• Rush AJ, Bose A. Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting. Depress. Anxiety21(1), 26–32 (2005).
   PubMed Web of Science ®Google Scholar
• Fernandez JL, Montgomery S, Francois C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics23(2), 155–167 (2005).
   PubMed Web of Science ®Google Scholar
• Sadri H, Mittman N. A qualitative review of recent economic evaluations of escitalopram. J. Pharm. Technol.23, 35–40 (2007).
   Google Scholar
• François C, Henrikkson F, Toumi M, et al. A Swedish pharmacoeconomic evaluation of escitalopram, a new SSRI: comparison of cost-effectiveness between escitalopram, PR-citalopram, fluoxetine and venlafaxine. Value Health5, 230 (2002) (Abstract).
   Google Scholar
• Sullivan PW, Valuck R, Saseen J, MacFall HM. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs18(13), 911–932 (2004).
   PubMed Web of Science ®Google Scholar
• Armstrong EP, Skrepnek GH, Haim Erder M. Cost–utility comparison of escitalopram and sertraline in the treatment of major depressive disorder. Curr. Med. Res. Opin.23(2), 251–258 (2007).
   PubMed Web of Science ®Google Scholar
• Hemels ME, Kasper S, Walter E, Einarson TR. Cost–effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria. Curr. Med. Res. Opin.20(6), 869–878 (2004).
   PubMed Web of Science ®Google Scholar
• Sorensen J, Stage KB, Damsbo N, Lay AL, Hemels ME. A Danish cost–effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care. Nord. J. Psychiatry61(2), 100–108 (2007).
   PubMed Web of Science ®Google Scholar
• Llorca PM, Fernandez JL. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost–effectiveness vs. venlafaxine extended-release formulation. Int. J. Clin. Pract.61(4), 702–710 (2007).
   PubMed Web of Science ®Google Scholar
• Doyle JJ, Casciano J, Arikian S et al. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost–effectiveness between venlafaxine, SSRIs and TCAs. Value Health4(1), 16–31 (2001).
   PubMedGoogle Scholar
• Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology50(1), 57–64 (2004).
   PubMed Web of Science ®Google Scholar
• Kulp W, von der Schulenburg JM, Greiner W. Cost–effectiveness of outpatient treatment in depressive patients with escitalopram in Germany. Eur. J. Health Econ.6(4), 317–321 (2005).
   PubMedGoogle Scholar
• Wade AG, Toumi I, Hemels ME. A probabilistic cost–effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr. Med. Res. Opin.21(4), 631–642 (2005).
   PubMed Web of Science ®Google Scholar
• Hemels ME, Sorenson J, Stage KB, Damsbo N, Le Lay A. Probabilistic cost–effectiveness model of escitalopram compared with citalopram and venlafaxine in the first-line treatment of major depressive disorder in Denmark. Presented at: The 46th Annual Meeting of the Scandinavian College of Neuropsychopharmacology. Helsingør, Denmark, 27–30 April 2005 (Poster)
   Google Scholar
• Wade AG, Toumi I, Hemels ME. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom. Clin. Ther.27(4), 486–496 (2005).
   PubMed Web of Science ®Google Scholar
• Francois C, Toumi M, Aakhus AM, Hansen K. A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost–effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway. Eur. J. Health Econ.4(1), 12–19 (2003).
   PubMedGoogle Scholar
• Danchenko N, Hansen K, Holsten F, Despiegel N. Cost–effectiveness of escitalopram versus citalopram and venlafaxine in treatment of severe depression in Norway. Presented at: The 6th World Congress on Health Economics (iHEA). Copenhagen, Denmark, 8–11 July 2007 (Abstract).
   Google Scholar
• Erder MH, Sharma D, Jonas JM. A comparison of total direct medical costs to managed care of escitalopram versus venlafaxine XR treatment in generalized anxiety disorder. Int. J. Neuropsychopharmacol.9(Suppl. 1), S120 (2006).
   Google Scholar
• Montgomery SA, Francois C, Despiegel N. Escitalopram versus placebo in social anxiety disorder (SAD): better effectiveness, lower costs and improved quality of life. Eur. Neuropsychopharmacol.13(Suppl. 4), S369 (2003) (Abstract P.363.038).
   Google Scholar
• Servant D, Montgomery SA, François C. Relapse in social anxiety disorder (SAD): costs and quality of life. Presented at: The 16th European College of Neuropsychopharmacology (ECNP). Prague, Czech Republic 10–24 September 2003 (abstract P.3.040).
   Google Scholar
• Gommoll C, Korotzer A, Chen S. Placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder. Presented at: The 26th Annual Meeting of the Anxiety Disorders Association of America. Miami, FL, USA, 23–26 March 2006 (Abstract).
   Google Scholar
• Lecrubier Y. The burden of depression and anxiety in general medicine. J. Clin. Psychiatry62(Suppl. 8), 4–9; discussion 10–11 (2001).
   PubMed Web of Science ®Google Scholar
• Ventura D, Armstrong EP, Skrepnek GH, Haim Erder M. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Curr. Med. Res. Opin.23(2), 245–250 (2007).
   PubMed Web of Science ®Google Scholar
• Hemels ME, Kasper S, Walter E, Einarson TR. Cost–effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria. Presented at: The 20th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Bordeaux, France, 22–25 August 2004 (Poster).
   Google Scholar
• Hemels ME, Kasper S, Walter E, Einarson TR. Cost–effectiveness of escitalopram versus citalopram in the treatment of severe depression. Ann. Pharmacother.38(6), 954–960 (2004).
   PubMed Web of Science ®Google Scholar
• Lieb R, Becker E, Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur. Neuropsychopharmacol.15(4), 445–452 (2005).
   PubMed Web of Science ®Google Scholar